PERSIST: Physician’s Evaluation of Restasis(®) Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review

BACKGROUND: Chronic dry eye disease often requires long-term therapy. Tear film alterations in the setting of dry eye may include reduced tear volume as well as an increase in inflammatory cytokines and osmolarity. Topical cyclosporine ophthalmic emulsion 0.05% (Restasis(®); Allergan Inc, Irvine, CA...

Descripción completa

Detalles Bibliográficos
Autores principales: Mah, Francis, Milner, Mark, Yiu, Samuel, Donnenfeld, Eric, Conway, Taryn M, Hollander, David A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514052/
https://www.ncbi.nlm.nih.gov/pubmed/23226002
http://dx.doi.org/10.2147/OPTH.S30261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514052/
https://www.ncbi.nlm.nih.gov/pubmed/23226002
http://dx.doi.org/10.2147/OPTH.S30261

Ejemplares similares